Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
To the Editor: Spontaneous reporting remains
the most used and efficient method of identifying new adverse drug reactions
(ADRs) in the postmarketing phase.1 We assessed
the magnitude of underreporting for serious ADRs in France by using data from
3 field pharmacoepidemiological studies.
The 3 studies we selected for analysis2-4 were
published in peer-reviewed journals, conducted in France in 1997 through 1998,
and based on a representative sample of the source population. Each study
was intended to estimate the number of hospitalizations caused by drugs. Therefore,
estimating the magnitude of underreporting was possible by comparing the reported
ADRs to the number of cases spontaneously reported to the French pharmacovigilance
system during the same period and within the same territory.
Bégaud B, Martin K, Haramburu F, Moore N. Rates of Spontaneous Reporting of Adverse Drug Reactions in France. JAMA. 2002;288(13):1588. doi:10.1001/jama.288.13.1585
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: